Table 1

Clinical and Angiographic Characteristics of Patients According to SYNTAX Score Tertiles

Tertile I, <7 (n = 854)Tertile II, ≥7 and <13 (n = 825)Tertile III, ≥13 (n = 948)p Value
Age, yrs59.3 ± 11.5 (854)60.0 ± 11.7 (825)62.6 ± 11.7 (948)<0.0001
Male63.9% (546/854)68.0% (561/825)70.4% (667/948)0.01
Hypertension64.5% (572/886)66.2% (545/823)66.0% (626/948)0.72
Diabetes mellitus25.4% (216/850)29.6% (243/821)30.3% (286/943)0.04
 Insulin-treated7.5% (64/850)7.8% (64/821)8.2% (77/943)0.88
Hypercholesterolemia56.6% (476/841)56.2% (458/815)55.8% (520/932)0.94
Current smoker38.2% (325/851)37.2% (306/823)31.1% (294/944)0.003
Previous myocardial infarction28.3% (237/836)26.9% (218/809)31.6% (294/931)0.09
Previous percutaneous coronary intervention51.1% (437/853)42.6% (351/823)38.8% (367/947)<0.0001
Renal dysfunction12.4% (99/796)15.0% (116/774)18.7% (166/888)0.002
Left ventricular ejection fraction56.1 ± 9.8 (671)54.3 ± 10.6 (645)50.6 ± 12.7 (767)<0.0001
Baseline troponin elevation51.3% (368/717)62.0% (440/710)67.7% (571/843)<0.0001
ST-segment deviation ≥1 mm22.5% (192/854)24.4% (201/825)28.9% (263/932)0.005
TIMI risk score
 Low (0–2)18.0% (122/678)15.6% (108/691)15.1% (115/762)0.29
 Intermediate (3–4)61.2% (415/678)60.9% (421/691)55.8% (425/762)0.06
 High (5–7)20.8% (141/678)23.4% (162/691)29.1% (222/762)0.0008
Antithrombotic medication
 Bivalirudin65.9% (563/854)66.1% (545/825)65.1% (617/948)0.89
 Unfractionated heparin20.8% (178/854)19.0% (157/825)19.2% (182/948)0.58
 Enoxaparin12.8% (109/854)13.2% (109/825)13.8% (131/948)0.80
 GPI65.7% (561/854)68.8% (568/825)68.1% (646/948)0.34
No. of vessel disease1.3 ± 0.5 (854)1.5 ± 0.6 (825)1.9 ± 0.8 (948)<0.0001
Multivessel disease22.4% (191/854)40.6% (335/825)66.9% (634/948)<0.0001
LAD disease34.4% (294/854)61.9% (511/825)75.5% (716/948)<0.0001
Cx disease38.5% (329/854)39.2% (323/825)55.3% (524/948)<0.0001
RCA disease51.6% (441/854)46.4% (383/825)59.4% (563/948)<0.0001
Left main coronary artery disease0.9% (8/854)0.6% (5/825)1.4% (13/948)0.26
No. of lesions2.8 ± 1.8 (853)3.7 ± 2.0 (824)4.6 ± 2.2 (946)<0.0001
Extent of disease, mm30.7 ± 20.6 (848)39.8 ± 26.8 (804)48.9 ± 28.8 (927)<0.0001
No. of treated vessels1.1 ± 0.3 (835)1.2 ± 0.4 (796)1.3 ± 0.5 (897)<0.0001
Any drug-eluting stent81.6% (697/854)87.2% (719/825)85.9% (814/948)0.004
Total no. of drug-eluting stents0.9 ± 0.6 (854)1.1 ± 0.7 (825)1.3 ± 0.8 (948)<0.0001
Any bare-metal stent12.3% (105/854)13.1% (108/825)16.5% (156/948)0.03
Total no. of bare-metal stents0.1 ± 0.4 (854)0.1 ± 0.4 (825)0.2 ± 0.5 (948)0.006
Lesion length >20 mm16.1% (159/987)18.9% (198/1,049)25.4% (332/1,307)<0.0001
Severe tortuosity0.4% (4/988)0.4% (4/1,066)0.2% (3/1,369)0.68
Thrombus10.9% (108/989)15.4% (164/1,065)19.0% (260/1,371)<0.0001
Severe calcification1.8% (17/967)2.3% (24/1,036)4.4% (60/1,352)0.0003
Ulceration4.1% (40/987)4.5% (48/1,065)4.8% (65/1,366)0.72
Aneurysm0.8% (8/989)1.1% (12/1,065)1.2% (16/1,366)0.67
Bifurcation present13.7% (135/988)23.8% (260/1,094)23.9% (327/1,367)<0.0001
Baseline QCA
 Reference vessel diameter, mm2.78 ± 0.57 (989)2.75 ± 0.53 (1,072)2.72 ± 0.54 (1,376)0.03
 Minimal lumen diameter, mm0.80 ± 0.47 (989)0.72 ± 0.46 (1,072)0.64 ± 0.46 (1,376)<0.0001
 Diameter stenosis, %71.2 ± 15.4 (989)73.8 ± 15.8 (1,072)76.0 ± 16.4 (1,376)<0.0001
Final QCA
 Reference vessel diameter, mm2.83 ± 0.56 (984)2.79 ± 0.53 (1,072)2.76 ± 0.54 (1,364)0.01
 Minimal lumen diameter, mm2.40 ± 0.55 (983)2.33 ± 0.53 (1,072)2.25 ± 0.58 (1,364)<0.0001
 Diameter stenosis, %15.3 ± 9.7 (983)16.5 ± 10.6 (1,072)18.4 ± 13.9 (1,364)<0.0001

Data are mean ± SD (N) or % (n/N). Renal dysfunction is defined as a calculated creatinine clearance rate <60 ml/min determined by the Cockcroft-Gault equation.

Cx = circumflex artery; GPI = glycoprotein IIb/IIIa inhibitor; LAD = left anterior descending artery; QCA = quantitative coronary angiography; RCA = right coronary artery; TIMI = Thrombolysis In Myocardial Infarction.